This was the stock's second consecutive day of losses.
Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
The stock's fall snapped a two-day winning streak.
Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.
Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...
In order from steepest decline to narrowest, the five unloved were Intel ( INTC 1.68%), MongoDB ( MDB 0.72%), Biogen ( BIIB 1 ...